Ocular Therapeutix™ to Present at Two Investor Conferences in March

Rhea-AI Summary

Ocular Therapeutix (NASDAQ: OCUL), a biopharmaceutical company focused on redefining the retina experience, has announced its participation in two major investor conferences in March 2025.

The company will first attend the TD Cowen 45th Annual Health Care Conference in Boston on Tuesday, March 4, 2025, where Executive Chairman, President and CEO Pravin U. Dugel, MD will participate in a fireside chat at 11:50 AM ET.

Following this, Ocular will join the Leerink Partners Global Healthcare Conference 2025 in Miami Beach on Monday, March 10, 2025, with another fireside chat scheduled for 10:00 AM ET, also featuring Dr. Dugel.

Investors can access live webcasts of both presentations through the Events and Presentations section on the Investor Relations page of the Ocular Therapeutix website.

News Market Reaction

+0.59%

1 alert

+0.59% News Effect

On the day this news was published, OCUL gained 0.59%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

BEDFORD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences in March:

TD Cowen 45^th Annual Health Care Conference Presentation Details
Fireside Chat Date: Tuesday, March 4, 2025
Fireside Chat Time: 11:50 AM ET
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: Boston, MA

Leerink Partners Global Healthcare Conference 2025
Fireside Chat Date: Monday, March 10, 2025
Fireside Chat Time: 10:00 AM ET
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: Miami Beach, FL

A live webcast of the fireside chat and presentation can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (axitinib intravitreal hydrogel, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA^®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral injection or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.

Follow the Company on its website, LinkedIn, or X.

The Ocular Therapeutix logo and DEXTENZA^® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

FAQ

When is Ocular Therapeutix (OCUL) presenting at the TD Cowen Healthcare Conference in 2025?

Ocular Therapeutix (OCUL) will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:50 AM ET in Boston, MA.

Who will represent Ocular Therapeutix (OCUL) at the March 2025 investor conferences?

Dr. Pravin U. Dugel, Executive Chairman, President and CEO of Ocular Therapeutix, will represent the company at both the TD Cowen and Leerink Partners conferences in March 2025.

How can investors access Ocular Therapeutix's (OCUL) March 2025 conference presentations?

Investors can access live webcasts of both presentations through the Events and Presentations section on the Investor Relations page of the Ocular Therapeutix website.

What is the date and time for Ocular Therapeutix's (OCUL) presentation at the Leerink Partners Conference?

Ocular Therapeutix (OCUL) will present at the Leerink Partners Global Healthcare Conference on Monday, March 10, 2025, at 10:00 AM ET in Miami Beach, FL.

Which investor conferences will Ocular Therapeutix (OCUL) attend in March 2025?

Ocular Therapeutix (OCUL) will attend two investor conferences in March 2025: the TD Cowen 45th Annual Health Care Conference in Boston and the Leerink Partners Global Healthcare Conference in Miami Beach.